PTGS2 and lung cancer: Similar results were obtained using lung cancer model [28] in that chronic COX-2 inhibition reduced antigen presenting cell mediated IL-10 secretion but enhanced IL-12 secretion in the tumor microenvironment and consequently reduced tumor size.